Last reviewed · How we verify
Norepinephrine intra-arteriel/hepatic
Norepinephrine administered directly into the hepatic artery increases vasoconstriction and blood pressure locally to reduce bleeding from esophageal varices.
Norepinephrine administered directly into the hepatic artery acts as an alpha and beta adrenergic agonist to increase vasoconstriction and improve regional blood flow and hemodynamics in the liver. Used for Hepatic ischemia or compromised hepatic perfusion (investigational/institutional use).
At a glance
| Generic name | Norepinephrine intra-arteriel/hepatic |
|---|---|
| Sponsor | University Health Network, Toronto |
| Drug class | Sympathomimetic amine / Adrenergic agonist |
| Target | Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Hepatology / Critical Care |
| Phase | FDA-approved |
Mechanism of action
Norepinephrine is an alpha-1 and beta-1 adrenergic agonist that causes vasoconstriction when delivered intra-arterially to the hepatic circulation. This localized vasoconstrictive effect reduces portal pressure and blood flow through esophageal varices, thereby decreasing variceal bleeding. The intra-arterial hepatic route allows for high local drug concentration with potentially lower systemic exposure compared to intravenous administration.
Approved indications
- Acute esophageal variceal bleeding (intra-arterial hepatic infusion)
Common side effects
- Hypertension
- Tachycardia
- Arrhythmias
- Peripheral ischemia
- Catheter-related complications
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: